SNCF Mobilites Medium-term Notes 1.10% until 25may31 News - SNBP

China's Basic Medical Insurance to Cover Sinobiopharma's Flagship Product

Basic Insurance to Cover 90 Percent of China's Urban Population of 600 Million by the End of 2010 NANTONG, China, Feb. 1 /PRNewswire-Asia/...

Chinese State Food and Drug Administration Approves Company Facility for Producing Solid Dosage Perindopril

NANTONG, China, Jan. 25 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma, Inc. ("Sinobiopharma" or, the "Company") (OTC:SNBP) (BULLETIN BOARD: SNBP...

Sinobiopharma Announces Second Quarter 2010 Financial Results

Revenue Increases to Approximately $2.1 Million; Net Income Increases to Approximately $1.1 Million NANTONG CITY, China, Jan. 19...

Zacks Equity Research Initiates Coverage on Sinobiopharma

NEW YORK, Nov. 19 /PRNewswire-Asia-FirstCall/ -- Zacks Equity Research has initiated investment research coverage on Sinobiopharma, Inc. (OTC...

Sinobiopharma has Production Rights to 23 Drugs Listed in China's National Essential Drugs List

All Drugs on List to be Covered by Basic Government Insurance That Will Cover 90 Percent of China's Population NANTONG, China, Nov. 16...

Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009

Company Posts First Net Profitable Quarter Since the Second Quarter 2008 NANTONG CITY, China, Oct. 21 /PRNewswire-Asia-FirstCall/...

Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material

NANTONG CITY, China, Oct. 8 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma, Inc. (OTC:SNBP) (BULLETIN BOARD: SNBP) ("Sinobiopharma") (the...

Sinobiopharma, Inc. Appoints New Chief Financial Officer and Director to the Board

NANTONG CITY, China, Sept. 29 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma, Inc. (OTC:SNBP) (BULLETIN BOARD: SNBP) ('Sinobiopharma' or, the...

Emissary Capital Group Initiates Coverage on Sinobiopharma

NEW YORK, Sept. 21 /PRNewswire/ -- Emissary Capital Group, Inc. has initiated investment research coverage on Sinobiopharma, Inc. (OTC Bulletin...

Sinobiopharma Receives Trademark Approval and Authentication From Chinese Government For Its 'Tai' Drug Series

NANTONG CITY, China, June 18 /PRNewswire/ -- Sinobiopharma, Inc. ("Sinobiopharma" or, the "Company") (OTC:SNBP) (BULLETIN BOARD: SNBP) is...

Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate

NANJING, China, May 21 /PRNewswire-FirstCall/ -- Sinobiopharma Inc. ("Sinobiopharma ", or "the Company") (OTC:SNBP) (BULLETIN BOARD: SNBP) is...

Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009

NANTONG CITY, China, May 20 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC:SNBP) (BULLETIN BOARD: SNBP) ("Sinobiopharma" or, the "Company...

Sinobiopharma Announces 350% Increase in Production of Its Flagship Drug in the First Quarter of 2009 Over the Same Period in 20

NANTONG CITY, China, May 14 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC:SNBP) (BULLETIN BOARD: SNBP) ("Sinobiopharma" or, the "Company...

Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril

NANTONG CITY, China, May 11 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC:SNBP) (BULLETIN BOARD: SNBP) ("Sinobiopharma" or, the "Company...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

SNCF Mobilites Medium-term Notes 1.10% until 25may31 (SNBP)

Professional-Grade Tools, for Individual Investors.

SNBP News

China's Basic Medical Insurance to Cover Sinobiopharma's Flagship Product

Chinese State Food and Drug Administration Approves Company Facility for Producing Solid Dosage Perindopril

Sinobiopharma Announces Second Quarter 2010 Financial Results

Zacks Equity Research Initiates Coverage on Sinobiopharma

Sinobiopharma has Production Rights to 23 Drugs Listed in China's National Essential Drugs List

Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009

Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material

Sinobiopharma, Inc. Appoints New Chief Financial Officer and Director to the Board

Emissary Capital Group Initiates Coverage on Sinobiopharma

Sinobiopharma Receives Trademark Approval and Authentication From Chinese Government For Its 'Tai' Drug Series

Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate

Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009

Sinobiopharma Announces 350% Increase in Production of Its Flagship Drug in the First Quarter of 2009 Over the Same Period in 20

Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril

SNBP Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

SNCF Mobilites Medium-term Notes 1.10% until 25may31 (SNBP) News

SNCF Mobilites Medium-term Notes 1.10% until 25may31 (SNBP)

Professional-Grade Tools, for Individual Investors.

SNBP News

China's Basic Medical Insurance to Cover Sinobiopharma's Flagship Product

Chinese State Food and Drug Administration Approves Company Facility for Producing Solid Dosage Perindopril

Sinobiopharma Announces Second Quarter 2010 Financial Results

Zacks Equity Research Initiates Coverage on Sinobiopharma

Sinobiopharma has Production Rights to 23 Drugs Listed in China's National Essential Drugs List

Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009

Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material

Sinobiopharma, Inc. Appoints New Chief Financial Officer and Director to the Board

Emissary Capital Group Initiates Coverage on Sinobiopharma

Sinobiopharma Receives Trademark Approval and Authentication From Chinese Government For Its 'Tai' Drug Series

Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate

Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009

Sinobiopharma Announces 350% Increase in Production of Its Flagship Drug in the First Quarter of 2009 Over the Same Period in 20

Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril

SNBP Discussion

Your Recent History